Skip to main content

Table 3 Tumor characteristics at diagnosis and variations after NAC

From: Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging

 

Pre-NAC CESM

Pre-NAC MRI

Post-NAC CESM

Post-NAC MRI

Mass enhancement

89% (41/46)

89% (41/46)

  

  Shape

  Round

24% (11/46)

26% (12/46)

15% (7/46)

15% (7/46)

  Oval

26% (12/46)

26% (12/46)

22% (10/46)

11% (5/46)

  Irregular

39% (18/46)

37% (17/46)

26% (12/46)

22% (10/46)

  None

  

26% (12/46)

41% (19/46)

  Margins

  Circumscribed

46% (21/46)

48% (22/46)

35% (16/46)

24% (11/46)

  Non-circumscribed

43% (20/46)

41% (19/46)

28% (13/46)

24% (11/46)

  None

  

26% (12/46)

41% (19/46)

Non-mass enhancement

11% (5/46)

11% (5/46)

  

  Distribution

  Regional

9% (4/46)

9% (4/46)

7% (3/46)

4% (2/46)

  Segmental

2% (1/46)

2% (1/46)

2% (1/46)

2% (1/46)

  None

  

2% (1/46)

4% (2/46)

Enhancement pattern

 Heterogeneous

83% (38/46)

80% (37/46)

61% (28/46)

43% (20/46)

 Clustered ring

17% (8/46)

20% (9/46)

11% (5/46)

11% (5/46)

 None

  

28% (13/46)

46% (21/46)

Contrast uptake

 Strong

78% (36/46)

83% (38/46)

2% (1/46)

4% (2/46)

 Intermediate

22% (10/46)

17% (8/46)

63% (29/46)

48% (22/46)

 Weak

  

7% (3/46)

2% (1/46)

 None

  

28% (13/46)

46% (21/46)

  1. NAC neoadjuvant chemotherapy, CESM contrast-enhanced spectral mammography, MRI magnetic resonance imaging